Review: 'Through the Shadowlands’ describes Julie Rehmeyer's ME/CFS Odyssey
I should note at the outset that this review is based on an audio version of the galleys and the epilogue from the finished work. Julie Rehmeyer sent me the final version as a PDF, but for some reason my text to voice software (Kurzweil) had issues with it. I understand that it is...
Discuss the article on the Forums.

Reducing bias in open-label trials where blinded outcome assessment is not feasible: strategies

Discussion in 'Other Health News and Research' started by Dolphin, Dec 8, 2014.

  1. Dolphin

    Dolphin Senior Member

    Messages:
    10,672
    Likes:
    28,181
    Probably a minority interest

    Free full text: http://www.trialsjournal.com/content/15/1/456

     
    Sasha, Simon, Valentijn and 3 others like this.
  2. Esther12

    Esther12 Senior Member

    Messages:
    8,449
    Likes:
    28,522
    Almost shouldn't need saying... lots of CFS research shows that it does.
     
    Dolphin, Sasha, Simon and 1 other person like this.
  3. Valentijn

    Valentijn Senior Member

    Messages:
    14,281
    Likes:
    45,814
    So if you can't blind the assessors, at least use objective indications for outcomes and adverse reactions :rolleyes:
     

See more popular forum discussions.

Share This Page